Back to results
US 8,999,296 B2Granted
Method of detecting bladder cancer
AssigneesKochi University, SBI Pharmaceuticals Co., Ltd.
InventorsKeiji Inoue, Masahiro Ishizuka, Tohru Tanaka
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneesKochi University, SBI Pharmaceuticals Co., Ltd.
InventorsKeiji Inoue, Masahiro Ishizuka, Tohru Tanaka
Estimating the term…
Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration.
A method of detecting bladder cancer comprising the sequential steps of:
A method of detecting bladder cancer comprising the sequential steps of:
A method of using 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these for producing an orally administrable bladder cancer detecting sensitizer, wherein oral administration of the sensitizer to a mammal delivers 10 to 50 mg ALA per kilo body weight in ALA hydrochloride equivalent or a molar equivalent of the derivative or the salt thereof prior to detecting fluorescence intensity in the bladder, and wherein the time from the oral administration of the sensitizer to the detection is between 2 hours to less than 5 hours.
A method of using 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these for producing an intravenously injectable bladder cancer detecting sensitizer, wherein intravenous injection of the sensitizer to a mammal delivers 10 to 50 mg ALA per kilo body weight in ALA hydrochloride equivalent or a molar equivalent of the derivative or the salt thereof prior to detecting fluorescence intensity in the bladder, and wherein the time from the intravenous injection of the sensitizer to the detection is between 2 hours to less than 5 hours.
Dependencies are inferred from the claim text.